Phaseline

Targets › PS

PS: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Nov 2026.

Open in Phaseline: the race on PS, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Bexion PharmaceuticalsBXQ-350
Saposin C (SapC) combined with phospholipid dioleoylphosphatidyl-serine (DOPS) forming a p
PSPhase 1Metastatic Colorectal CarcinomaNov 2026

Conditions

Metastatic Colorectal Carcinoma (1)

Modalities

small molecule (1)

Companies

Bexion Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.